BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solitano V, Parigi TL, Ragaini E, Danese S. Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. Expert Opin Investig Drugs 2021;30:1037-46. [PMID: 34449288 DOI: 10.1080/13543784.2021.1974396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Brayden DJ. Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials. BioDrugs 2022. [DOI: 10.1007/s40259-022-00562-6] [Reference Citation Analysis]
2 Liu F, Yao Y, Wang Q, Zhang F, Wang M, Zhu C, Lin C. Nigakinone alleviates DSS ‐induced experimental colitis via regulating bile acid profile and FXR / NLRP3 signaling pathways. Phytotherapy Research. [DOI: 10.1002/ptr.7588] [Reference Citation Analysis]
3 Wang M, Huang X, Kang Z, Huang J, Wei S, Zhao H, Zhong Y, Liu D. Mechanism of Sishen-Pill-Regulated Special Memory T and mTfh Cell via Involving JAK/STAT5 Pathway in Colitis Mice. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-12. [DOI: 10.1155/2022/6446674] [Reference Citation Analysis]